We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note FDA-cleared MRD assay; only FDA-cleared MRD assay for multiple myeloma. Used in 180+ active biopharma trials. Company announced June 2026 intent to pursue separation of MRD and Immune Medicine businesses.
TCR-depleting antibody program
Preclinical · ActiveModality: antibody
Target TCR (T-cell receptor)
Indications
ankylosing spondylitis(Preclinical)
Status note Per 10-K business section, company completed a preclinical data package for the TCR-depleting antibody program in ankylosing spondylitis.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
H. Lee Moffitt Cancer Center and Research Institute
—
Multiple Myeloma
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 7 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.